Activity against the coccidial pathogen Eimeria tenella in chickens has been discovered among a2 adrenergic agonists. The clonidine analog 7-bromo-N-(2-imidazolidinylidene)-1H-indazol-6-amine was active in feed at 7.5 ppm, a concentration similar to the use levels of potent commercial agents, e.g., maduramicin. Additional a2 agonists were also found to have anticoccidial activity, for example, the catecholamine nordefrin, which is chemically unrelated to clonidine. However, al agonists and a antagonists were inactive. These observations imply that anticoccidial effects reflect involvement of a receptor with the characteristics of the vertebrate a2 adrenoceptor. a2 agonists that permeate the blood-brain barrier (like clonidine) inhibit feed intake at efficacious levels, whereas those that are restricted to the peripheral compartment (such as catecholamines) do not inhibit feed intake as much. Hence, anticoccidial efficacy may be a peripheral adrenergic effect whereas depression of feed intake is likely centrally mediated.
Coccidiosis, an intestinal disease of great economic importance in the poultry industry, is caused by intracellular protozoan parasites of the genus Eimeria. Although more than 20 different anticoccidial agents have been commercialized, the current drugs of choice belong to a single class: the polyether ionophores. Because of the ever-present threat that coccidia will develop resistance to these agents, there is a continuing need to discover new classes of anticoccidial agents.
In the course of evaluating compounds from our files, 7-bromo-N-(2-imidazolidinylidene)-lH-indazol-6-amine (compound I) proved to be active against Eimeria tenella infections in chickens; however, it led to low weight gains. Compound I was prepared originally as a clonidine analog. Clonidine produces a variety of effects, owing to its a2 adrenergic agonist activities, and has found clinical use as an antihypertensive agent (7) . Compound I also shows a2 agonist properties (3) . We therefore explored the possibility that the observed anticoccidial activity was dependent upon stimulation of a2 adrenoceptors. If this were the case, it would follow that other a2 agonists, those structurally unrelated to clonidine, would show this effect. Conversely, a1 adrenergic agonists and a antagonists should be inactive. To test this hypothesis, we evaluated the anticoccidial activities of a variety of a adrenergic agents.
We discovered that (i) among a adrenergic agents, anticoccidial activity is associated only with a2 agonists; (ii) a2 agonists other than clonidine analogs are also effective; and (iii) a2 agonists that cannot cross the blood-brain barrier, such as catecholamines, are effective and at the same time not as weight suppressive.
MATERIALS AND METHODS General. Melting points are uncorrected. Yields were not maximized. All compounds had 'H nuclear magnetic resonance spectra that were consistent with their assigned structures. The following agents were either purchased from * Corresponding author. commercial sources (e.g., Sigma Chemical Co.) or prepared by methods described in the literature: clonidine (Chemical Abstracts Registry no. 4205-91-8), epinephrine (base) (51-43-4), guanabenz (5051-62-7), guanfacine (29110-48-3), methoxamine hydrochloride (61-16-5), nordefrin (base) (6539-57-7), norepinephrine hydrochloride (51-41-2), phenylephrine (59-42-7), phentolamine (50-60-2), prazosin hydrochloride (19237-84-4), St9l hydrochloride (59465-42-8), St1913 (52115-81-3), tetrahydrozoline hydrochloride (522-48-5), tolazoline (59-98-3), UK14304 tartrate (59803-99-5), and yohimbine (146-48-5).
7-Bromo-lH-indazol-6-amine. A solution of 5.0 g (38 mmol) of 1H-indazol-6-amine and 100 ml of acetic acid (AcOH) was cooled to 15°C. With magnetic stirring, a solution of 6.33 g (2.03 ml, 40 mmol) of Br2 and 20 ml of AcOH was added dropwise over a period of 1 h while the temperature was maintained at 15°C. The ensuing precipitate of the HBr salt was filtered, washed successively with AcOH and diethyl ether, and allowed to dry. The salt was taken up in H20, the solution was adjusted to pH 8 with NaHCO3, and the aqueous solution was then extracted with ethyl acetate. The organic phase was washed with saturated aqueous NaCl, dried over anhydrous MgSO4, filtered, and evaporated to furnish 2.2 g (28%) of 7-bromo-lH-indazol-6-amine (mp, 193 to 195°C) . A small portion was recrystallized from 2-propanol for analysis (mp, 193 to 195°C) .
The composition of C7H6BrN3 (212.05) calculated was C, 39.65%; H, 2.84%; and N, 19.81%. That found was C, 39.28%; H, 2.81%; and N, 19.48%.
7-Bromo-lH-indazol-6-yl isothiocyanate. In a three-neck, round-bottom flask equipped with a mechanical stirrer and appropriate traps and under an N2 atmosphere, a slurry of 10 g (47 mmol) of 7-bromo-lH-indazol-6-amine and 425 ml of H20 was treated with 6.3 g (4.2 ml, 55 mmol) of CSC12 at room temperature and stirred for 4 h. The mixture was poured with stirring into 1 N NaOH, and this new mixture was then filtered to give a brown solid. The solid was taken up in diethyl ether, and the insolubles were filtered. The organic phase was dried over anhydrous Na2SO4, and the solvent was evaporated to give crude isothiocyanate; the yield was 5.4 g (45%). This product was not further purified and was used directly in the preparation described below.
1-(7-Bromo-lH-indazol-6-yl)thiourea. A three-neck, roundbottom flask containing 15 ml of methanol (MeOH) was cooled to -20°C and then charged with approximately S ml of liquid NH3. The cooling bath was removed, and 1.0 g (3.9 mmol) of the isothiocyanate described above was added. The solution was allowed to warm to room temperature; a precipitate resulted. The colorless solid was filtered and air dried to furnish 623 mg (58%) of 1-(7-bromo-1H-indazol-6-yl)thiourea (mp, 220 to 221°C).
The composition of C8H7BrN4S (271.13) calculated was C, 35.44%; H, 2.60%; and N, 20.67%. That found was C, 35.15%; H, 2.40%; and N, 20.00%.
S-Methyl-1-(7-bromo-lH-indazol-6-yl)isothiourea hydroiodide. A solution of 1.35 g (5.0 mmol) of the thiourea just described, 0.75 g (0.33 ml, 5.3 mmol) of CH3I, and 12 ml of MeOH was heated under reflux for 1 h. Upon cooling to room temperature, the reaction solution produced a precipitate. The volatile components were evaporated under reduced pressure, and the ensuing residue was crystallized from MeOH-ethyl acetate to give 1.36 g (66%) of S-methyl-1-(7-bromo-lH-indazol-6-yl)isothiourea hydroiodide (mp, 214 to 215°C).
The composition of C9H10BrIN4S (413.07) calculated was C, 26.17%; H, 2.26%; and N, 13.56%. That found was C, 26.42%; H, 2.26%; and N, 13.66%.
Compound I. With appropriate traps to collect evolving methanethiol, a solution of 8.7 g (21 mmol) of the isothiourea just described, 2.7 g (3.2 ml, 44 mmol) of 1,2-ethanediamine, and 95 ml of MeOH was heated under reflux and under a rapid flow of N2 with vigorous stirring for 20 h. If the N2 flow is insufficient, the residual methanethiol may reduce the Br atom in the indazole ring with the result of recovery of substantial amounts of N-(2-imidazolidinylidene)-lH-indazol-6-amine in the workup. MeOH was added from time to time to maintain the volume at approximately 100 ml. The reaction solution was concentrated to about 10 ml; 85 ml of 2-propanol was added, and heating was continued for 2 h. A precipitate began to form, and the reaction mixture was allowed to cool to room temperature. The solid product was filtered, taken up in H20, and heated for 30 min. Upon cooling, crystals formed. These were filtered and air dried to furnish 3.5 g (59o) of phenylephrine and methoxamine (pure ot1 agonists); prazosin (a pure a1 antagonist); tolazoline and phentolamine (each with ax1 and (x2 antagonist activities); and yohimbine (a pure a2 antagonist). The chemical structures of these compounds are shown in Fig. 1 . The results were that only those compounds with at2 agonist activity-compound I, clonidine, epinephrine, and nordefrin-were effective against E. tenella. Table 1 shows the results obtained with the (x2 agonists.
Preliminary studies indicated that still other compounds with (X2 agonist activity also have anticoccidial activity, i.e., guanabenz, guanfacine, St9l, St1913, tetrahydrozoline, and UK14304 tartrate. On the other hand, norepinephrine appears to be inactive against E. tenella.
Weight gain. Clonidine is known to lower food intake in humans (6), rats (2) , and dogs (2), resulting in decreased weight gain (5) . The weight gain data from the primary efficacy trials (Table 1) indicated that for compound I and clonidine, anticoccidial activity was linked to weight suppression; however, these data are difficult to interpret because they reflect the combined weight-suppressive effects of the drug and the infection. To confirm this weightsuppressive effect in uninfected chickens, to differentiate effects on feed intake from feed utilization, and to gain a clearer, statistically valid indication of performance effects in chickens, a 10-day growth performance trial with compound I and clonidine was conducted with uninfected birds. The results are shown in Table 2 . With compound I above 1 ppm, there was a significant dose-related weight suppression. This weight suppression was due to depressed feed intake; feed conversion was unaffected. A similar pattern was seen with clonidine but at higher dose levels. We have confirmed that clonidine-type agents suppress feed intake, yet evidence from efficacy trials indicates that the catecholamines do not share this effect, at least to the same degree (Table 1) . For example, comparing treatments giving a high degree of lesion control relative to each other, we found that nordefrin at 500 ppm resulted in weight gain significantly higher than that of clonidine at 500 ppm (P < 0.01) and that of compound I at 15 ppm (P < 0.1). Similarly, at the next lower set of doses, nordefrin at 250 ppm gave superior weight gain compared with that of clonidine at 250 ppm (P < 0.01) and that of compound I at 7.5 ppm (P < 0.01).
A major difference between the clonidine-type and catecholamine at agonists is that the former are lipophilic and can cross the blood-brain barrier readily, whereas the latter are hydrcphilic and are restricted to the peripheral compartment. Thus, a hypothesis consistent with the observations made in this study is that depression of feed intake is a centrally mediated effect while anticoccidial activity is peripherally mediated. The present work has established a link between a2 agonism and anticoccidial activity. This raises several questions concerning the nature of this association, some of which are addressed in the accompanying report (3). 
